These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
24. Safety and therapeutic effect of metronomic chemotherapy with cyclophosphamide and celecoxib in advanced breast cancer patients. Perroud HA; Rico MJ; Alasino CM; Queralt F; Mainetti LE; Pezzotto SM; Rozados VR; Scharovsky OG Future Oncol; 2013 Mar; 9(3):451-62. PubMed ID: 23469980 [TBL] [Abstract][Full Text] [Related]
25. Phase II clinical trial of bevacizumab and low-dose metronomic oral cyclophosphamide in recurrent ovarian cancer: a trial of the California, Chicago, and Princess Margaret Hospital phase II consortia. Garcia AA; Hirte H; Fleming G; Yang D; Tsao-Wei DD; Roman L; Groshen S; Swenson S; Markland F; Gandara D; Scudder S; Morgan R; Chen H; Lenz HJ; Oza AM J Clin Oncol; 2008 Jan; 26(1):76-82. PubMed ID: 18165643 [TBL] [Abstract][Full Text] [Related]
26. Metronomic chemotherapy for cancer treatment: a decade of clinical studies. Romiti A; Cox MC; Sarcina I; Di Rocco R; D'Antonio C; Barucca V; Marchetti P Cancer Chemother Pharmacol; 2013 Jul; 72(1):13-33. PubMed ID: 23475105 [TBL] [Abstract][Full Text] [Related]
27. Bevacizumab plus low-dose metronomic oral cyclophosphamide in heavily pretreated patients with recurrent ovarian cancer. Sánchez-Muñoz A; Mendiola C; Pérez-Ruiz E; Rodríguez-Sánchez CA; Jurado JM; Alonso-Carrión L; Ghanem I; de Velasco G; Quero-Blanco C; Alba E Oncology; 2010; 79(1-2):98-104. PubMed ID: 21079407 [TBL] [Abstract][Full Text] [Related]
28. Bevacizumab in combination with metronomic chemotherapy in patients with anthracycline- and taxane-refractory breast cancer. García-Sáenz JA; Martín M; Calles A; Bueno C; Rodríguez L; Bobokova J; Custodio A; Casado A; Díaz-Rubio E J Chemother; 2008 Oct; 20(5):632-9. PubMed ID: 19028628 [TBL] [Abstract][Full Text] [Related]
29. Metronomic oral cyclophosphamide prednisolone chemotherapy is an effective treatment for metastatic hormone-refractory prostate cancer after docetaxel failure. Ladoire S; Eymard JC; Zanetta S; Mignot G; Martin E; Kermarrec I; Mourey E; Michel F; Cormier L; Ghiringhelli F Anticancer Res; 2010 Oct; 30(10):4317-23. PubMed ID: 21036758 [TBL] [Abstract][Full Text] [Related]
30. Efficacy and safety of low-dose metronomic chemotherapy with capecitabine in heavily pretreated patients with metastatic breast cancer. Fedele P; Marino A; Orlando L; Schiavone P; Nacci A; Sponziello F; Rizzo P; Calvani N; Mazzoni E; Cinefra M; Cinieri S Eur J Cancer; 2012 Jan; 48(1):24-9. PubMed ID: 21775129 [TBL] [Abstract][Full Text] [Related]
31. Antiangiogenic metronomic therapy for children with recurrent embryonal brain tumors. Peyrl A; Chocholous M; Kieran MW; Azizi AA; Prucker C; Czech T; Dieckmann K; Schmook MT; Haberler C; Leiss U; Slavc I Pediatr Blood Cancer; 2012 Sep; 59(3):511-7. PubMed ID: 22147459 [TBL] [Abstract][Full Text] [Related]
32. Phase II study of combining sorafenib with metronomic tegafur/uracil for advanced hepatocellular carcinoma. Hsu CH; Shen YC; Lin ZZ; Chen PJ; Shao YY; Ding YH; Hsu C; Cheng AL J Hepatol; 2010 Jul; 53(1):126-31. PubMed ID: 20416968 [TBL] [Abstract][Full Text] [Related]
33. A phase I trial of oral metronomic vinorelbine plus capecitabine in patients with metastatic breast cancer. Saridaki Z; Malamos N; Kourakos P; Polyzos A; Ardavanis A; Androulakis N; Kalbakis K; Vamvakas L; Georgoulias V; Mavroudis D Cancer Chemother Pharmacol; 2012 Jan; 69(1):35-42. PubMed ID: 21590447 [TBL] [Abstract][Full Text] [Related]
34. Exploratory predictive and prognostic factors in advanced breast cancer treated with metronomic chemotherapy. Miscoria M; Tonetto F; Deroma L; Machin P; Di Loreto C; Driol P; Minisini AM; Russo S; Andreetta C; Mansutti M; Damante G; Fasola G; Puglisi F Anticancer Drugs; 2012 Mar; 23(3):326-34. PubMed ID: 22129512 [TBL] [Abstract][Full Text] [Related]
35. Preliminary evaluation of children treated with metronomic chemotherapy and valproic acid in a low-income country: Metro-Mali-02. Traore F; Togo B; Pasquier E; Dembélé A; André N Indian J Cancer; 2013; 50(3):250-3. PubMed ID: 24061467 [TBL] [Abstract][Full Text] [Related]
36. A prospective randomized phase II study comparing metronomic chemotherapy with chemotherapy (single agent cisplatin), in patients with metastatic, relapsed or inoperable squamous cell carcinoma of head and neck. Patil VM; Noronha V; Joshi A; Muddu VK; Dhumal S; Bhosale B; Arya S; Juvekar S; Banavali S; D'Cruz A; Bhattacharjee A; Prabhash K Oral Oncol; 2015 Mar; 51(3):279-86. PubMed ID: 25578869 [TBL] [Abstract][Full Text] [Related]
37. Phase II study of lapatinib and capecitabine in second-line treatment for metastatic pancreatic cancer. Wu Z; Gabrielson A; Hwang JJ; Pishvaian MJ; Weiner LM; Zhuang T; Ley L; Marshall JL; He AR Cancer Chemother Pharmacol; 2015 Dec; 76(6):1309-14. PubMed ID: 26507197 [TBL] [Abstract][Full Text] [Related]
38. A Decade of Experience in Developing Preclinical Models of Advanced- or Early-Stage Spontaneous Metastasis to Study Antiangiogenic Drugs, Metronomic Chemotherapy, and the Tumor Microenvironment. Kerbel RS Cancer J; 2015; 21(4):274-83. PubMed ID: 26222079 [TBL] [Abstract][Full Text] [Related]
39. High circulating endothelial progenitor levels associated with poor survival of advanced hepatocellular carcinoma patients receiving sorafenib combined with metronomic chemotherapy. Shao YY; Lin ZZ; Chen TJ; Hsu C; Shen YC; Hsu CH; Cheng AL Oncology; 2011; 81(2):98-103. PubMed ID: 21986371 [TBL] [Abstract][Full Text] [Related]
40. Metronomic oral vinorelbine as first-line treatment in elderly patients with advanced non-small cell lung cancer: results of a phase II trial (MOVE trial). Camerini A; Puccetti C; Donati S; Valsuani C; Petrella MC; Tartarelli G; Puccinelli P; Amoroso D BMC Cancer; 2015 May; 15():359. PubMed ID: 25943747 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]